Johnson & Johnson (NYSE: JNJ)

Drug Manufacturers - General · New Brunswick, NJ, United States · Founded 1886

$400.0B

Market Cap

$94.19B

Revenue

131,900

Employees

$26.8B

Net Income

📊 Key Statistics for Johnson & Johnson (JNJ)

Market capitalization: $400.0 billion
Annual revenue: $94.19 billion
Net income: $26.8 billion
Employees: 131,900
Sector: Healthcare
Headquarters: New Brunswick, United States
Founded: 1886

Source: Statvoo company profile for Johnson & Johnson. Browse all 500+ companies

📋 About Johnson & Johnson

J&J is one of the world's largest healthcare companies, with about $85 billion in 2023 revenue across pharmaceuticals and medical devices. The company spun off its consumer health division (Band-Aid, Tylenol, Neutrogena) as Kenvue in 2023, fundamentally reshaping its profile. Pharma now drives roughly 60% of revenue, led by immunology blockbuster Stelara and oncology drugs. J&J has over 130,000 employees worldwide.

jnj.com analysis · Visit website →

💰 How Johnson & Johnson Makes Money

Two segments post-Kenvue: Innovative Medicine (pharmaceuticals) and MedTech (surgical instruments, orthopedics, vision care). Pharma carries the higher margins and growth, while MedTech provides steady, procedure-driven revenue. The company spends over $15 billion annually on R&D.

📜 Key Milestones

Three Johnson brothers founded the company in 1886 in New Brunswick, New Jersey. J&J's handling of the 1982 Tylenol poisoning crisis became the gold standard for corporate crisis management. The company has increased its dividend for over 60 consecutive years, making it a Dividend King. The Kenvue separation in 2023 was the biggest strategic shift in decades.

📊 Financial Overview

Market Capitalization	$400.0B
Annual Revenue	$94.19B
Net Income	$26.8B
Profit Margin	28%
Revenue per Employee	$714102K
Stock Exchange	NYSE
Ticker Symbol	JNJ

Financial data is approximate and based on most recent annual filings.

💡 Did You Know?

J&J's consumer health business — the part most people associate with the brand — was actually the smallest and lowest-margin segment before the spinoff. The company has faced over 100,000 lawsuits related to talc products and opioids, with settlements and reserves totaling tens of billions. J&J holds more AAA credit ratings than most sovereign nations — it's one of only two U.S. companies with that distinction (Microsoft is the other).

📝 Analyst Take

Post-Kenvue, J&J is a cleaner pharma/medtech story, but the Stelara patent cliff in 2025 is a real headwind. The pipeline needs to deliver, and the litigation overhang isn't going away anytime soon.

❓ Frequently Asked Questions